Back to top
more

CRISPR Therapeutics (CRSP)

(Delayed Data from NSDQ)

$56.16 USD

56.16
1,744,760

+0.60 (1.08%)

Updated Apr 18, 2024 04:00 PM ET

After-Market: $56.95 +0.79 (1.41%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is Trending Stock CRISPR Therapeutics AG (CRSP) a Buy Now?

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $57.96, marking a -1.29% move from the previous day.

bluebird (BLUE) Underperforms Industry YTD Amid Challenges

by Zacks Equity Research

bluebird (BLUE) plunges 25% year to date as it struggles to fuel the growth of its complex and expensive gene therapies.

Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex

by Zacks Equity Research

Vertex (VRTX) is set to acquire Alpine Immune Sciences (ALPN) for $65 per share in cash. The transaction is likely to close by second-quarter 2024.

Charles River (CRL) Forges Collaboration With Ship of Theseus

by Zacks Equity Research

Charles River (CRL) is set to perform plasmid production for Ship of Theseus.

CRISPR Therapeutics AG (CRSP) Exceeds Market Returns: Some Facts to Consider

by Zacks Equity Research

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $65.19, marking a +1.72% move from the previous day.

CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) concluded the recent trading session at $65.06, signifying a +0.71% move from its prior day's close.

Vertex (VRTX) Moves Kidney Disease Drug to Phase 3 Development

by Zacks Equity Research

Vertex (VRTX) advances inaxaplin to late-stage development. It will evaluate the drug in lower age groups and will enroll patients aged 10 years and older with APOL1-mediated kidney disease.

bluebird (BLUE) Misses on Q4 Revenues, Provides Portfolio Updates

by Zacks Equity Research

bluebird bio (BLUE) revenues miss the Zacks Consensus Estimate in the fourth quarter. The company progresses with the launch of its three approved gene therapies.

CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) reachead $71.08 at the closing of the latest trading day, reflecting a -0.74% change compared to its last close.

Vertex (VRTX) Continues to Diversify Beyond CF Franchise

by Zacks Equity Research

While CF remains the main area of focus for Vertex Pharmaceuticals (VRTX), it is seeing success in the development of its non-CF pipeline candidates.

Vertex (VRTX) Kidney Disease Drug to Enter Clinical Development

by Zacks Equity Research

Vertex Pharmaceuticals (VRTX) plans to begin a phase I study on VX-407 in autosomal dominant polycystic kidney disease later this month.

CRISPR Therapeutics (CRSP) Down 13.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CRISPR Therapeutics AG (CRSP) Outperforms Broader Market: What You Need to Know

by Zacks Equity Research

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $71.96, marking a +0.69% move from the previous day.

bluebird (BLUE) Gets $175 Million Loan From Hercules, Shares Up

by Zacks Equity Research

bluebird (BLUE) obtains a $175 million five-year, term loan facility from Hercules that stretches its cash runaway by two years. The company's shares rise on the news.

CRISPR (CRSP) Q4 Earnings Top on Collaboration Revenues, Stock Up

by Zacks Equity Research

CRISPR (CRSP) gains on encouraging fourth-quarter 2023 results, beating both earnings and revenue estimates on the back of collaboration revenues received from Vertex.

Amphastar (AMPH) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Amphastar's (AMPH) revenues in the fourth quarter of 2023 are expected to have been driven by the sales of its pharmaceutical products.

BeiGene (BGNE) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

BeiGene's (BGNE) revenues in fourth-quarter 2023 are expected to have been driven by the sales of its marketed pharmaceutical products.

Altimmune (ALT) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Altimmune's (ALT) fourth-quarter 2023 earnings call, investors' focus is likely to be on the company's progress with the development of its lead pipeline candidate, pemvidutide.

CRISPR Therapeutics AG (CRSP) Moves 6.9% Higher: Will This Strength Last?

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Vericel Corporation (VCEL) to Report Q4 Results: Wall Street Expects Earnings Growth

by Zacks Equity Research

Vericel Corporation (VCEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotech Stock Roundup: BIIB's Q4 Results, CBAY Up on GILD's Acquisition & Other Updates

by Zacks Equity Research

Earnings from Biogen (BIIB) and CymaBay (CBAY) are in focus in the biotech sector.

CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On CRISPR's (CRSP) fourth-quarter 2023 earnings call, investors' focus is likely to be on the company's progress with the launch activities of the newly approved gene therapy, Casgevy (exa-cel).

Vertex (VRTX), CRSP's Casgevy Gets EU Nod for Two Blood Disorders

by Zacks Equity Research

Following the approval of Vertex (VRTX) and CRISPR Therapeutics' (CRSP) Casgevy, approximately 8,000 patients, 12 years of age and older, with SCD or TDT in Europe, become potentially eligible for treatment.

CRISPR Therapeutics AG (CRSP) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.